Searching for therapeutic synergy in primary effusion lymphoma

Primary effusion lymphoma (PEL) is a rare, fatal form of aggressive B-cell lymphoma caused by Kaposi's sarcoma-associated herpesvirus (KSHV). The disease most commonly occurs in immunocompromised patients, such as those with HIV and the elderly. Because current treatment options are not effective, there is a great need for new PEL therapies.

In this issue of the Journal of Clinical Investigation, Juan Carlos Ramos and colleagues at the University of Miami used an immunocompromised mouse model of PEL to determine the efficacy of Bortezomib/Vorinostat combination therapy, two drugs that are currently being used to treat and cutaneous , respectively. They found that this treatment combination reactivated virus-induced cell lysis and induced PEL cell death, increasing the lifespan of mice with PEL tumors.

These findings indicate that this drug combination could potentially be beneficial in immunocompromised patients with KSHV-associated malignancies.

More information: Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma, J Clin Invest. doi:10.1172/JCI64503

add to favorites email to friend print save as pdf

Related Stories

Scientists tackle viral mysteries

Jun 29, 2009

Scientists know that some cancers are triggered by viruses, which take over cellular systems and cause uncontrolled cell growth. Doctors - and patients who get shingles late in life - have also known for many years that ...

Recommended for you

Dog's epigenome gives clues to human cancer

56 minutes ago

The bond between humans and dogs is strong and ancient. From being the protector of the first herds in a faithful pet, dogs and people share many aspects of life. The relationship between the two species ...

Study pinpoints microRNA tied to colon cancer tumor growth

16 hours ago

Researchers at the University of Minnesota have identified microRNAs that may cause colon polyps from turning cancerous. The finding could help physicians provide more specialized, and earlier, treatment before colon cancer ...

User comments